Aaron Koenig

Aaron Koenig, M.D.

Chief Medical Officer

Aaron serves as Chief Medical Officer at Syndeio Biosciences. He previously served as Chief Medical Officer at Delix Therapeutics and, before that, as Vice President of Early Medical Science (Clinical Development) at Sage Therapeutics, where he helped to design and oversee Sage’s clinical-stage neuropsychiatry programs, including programs focused on a range of neurodegenerative and neurodevelopmental disorders. Prior to joining the biopharmaceutical industry, Aaron was a clinical investigator at the Massachusetts Alzheimer’s Disease Research Center and practiced as a clinician in the MGH Memory Disorders Unit in the Department of Neurology at Massachusetts General Hospital.

Aaron received his M.D. from the University of Pennsylvania School of Medicine, and completed a residency in adult psychiatry at Western Psychiatric Institute & Clinic of UPMC, where he also served as a Chief Resident for Research. He subsequently completed a clinical fellowship in geriatric psychiatry at the Hospital of the University of Pennsylvania, followed by a post-doctoral research fellowship in psychiatric genetics and translational research at the Harvard T.H. Chan School of Public Health. Aaron is a diplomate of the American Board of Psychiatry and Neurology (ABPN), and has been involved in clinical and translational research throughout his career, with a particular focus on the development of treatments for neuropsychiatric disorders with high unmet need.